Biogen Makes $200M Alzheimer's Drug Deal with Proteostasis


Dec 10, 2013

Massachusetts-based Proteostasis has entered into a worldwide collaboration with Biogen Idec to develop drugs that could treat certain neurodegenerative disorders, such as Alzheimer’s and Parkinson’s, by blocking an enzyme known as Usp14

According to Proteostasis, it will receive an initial upfront payment from Biogen (a leader in the multiple sclerosis field), along with an equity investment, and is eligible for research funding support and future development and commercial milestones that could result in total payments of up to $200 million, as well as tiered royalties.

Read the Proteostasis press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments